ElevateBio gene therapy lowers levels of toxic protein in mice with Huntington’s disease
ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in mice with Huntington’s disease by more than 80%.
ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in mice with Huntington’s disease by more than 80%.
